Kurzfassung

A randomized, open-label, phase III study of RPR109881 IV every 3 weeks versus capecitabine (Xeloda) tablets twice daily for 2 weeks cycles in patients with metastatic breast cancer progressing after taxanes and anthacyclines XRP9881B/3001